141 related articles for article (PubMed ID: 24383331)
1. Cilazapril stability in the presence of hydrochlorothiazide in model mixtures and fixed dose combination.
Paszun SK; Stanisz BJ; Gradowska A
Acta Pol Pharm; 2013; 70(6):1079-85. PubMed ID: 24383331
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of degradation of imidapril hydrochloride in finished dosage formulations.
Stanisz B; Regulska K
Acta Pol Pharm; 2013; 70(4):737-42. PubMed ID: 23923397
[TBL] [Abstract][Full Text] [Related]
3. A comparative study between hot-melt extrusion and spray-drying for the manufacture of anti-hypertension compatible monolithic fixed-dose combination products.
Kelleher JF; Gilvary GC; Madi AM; Jones DS; Li S; Tian Y; Almajaan A; Senta-Loys Z; Andrews GP; Healy AM
Int J Pharm; 2018 Jul; 545(1-2):183-196. PubMed ID: 29730176
[TBL] [Abstract][Full Text] [Related]
4. Multicriteria Optimization Methodology in Stability-Indicating Method Development of Cilazapril and Hydrochlorothiazide.
Šljivic J; Protic A; Otaševic B; Golubovic J; Zecevic M; Krmar J
J Chromatogr Sci; 2017 Jul; 55(6):625-637. PubMed ID: 28334985
[TBL] [Abstract][Full Text] [Related]
5. Influence of pH modifiers on the dissolution and stability of hydrochlorothiazide in the bi- and three-layer tablets.
Blatnik SU; Dreu R; Srčič S
Acta Pharm; 2015 Dec; 65(4):383-97. PubMed ID: 26677896
[TBL] [Abstract][Full Text] [Related]
6. RP-HPLC method for simultaneous estimation of bisoprolol fumarate and hydrochlorothiazide in tablet formulation.
Joshi SJ; Karbhari PA; Bhoir SI; Bindu KS; Das C
J Pharm Biomed Anal; 2010 Jul; 52(3):362-71. PubMed ID: 19926421
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceutical solid-state kinetic stability investigation by using moisture-modified Arrhenius equation and JMP statistical software.
Fu M; Perlman M; Lu Q; Varga C
J Pharm Biomed Anal; 2015 Mar; 107():370-7. PubMed ID: 25656488
[TBL] [Abstract][Full Text] [Related]
8. Stability study of losartan/hydrochlorothiazide tablets.
Lusina M; Cindrić T; Tomaić J; Peko M; Pozaić L; Musulin N
Int J Pharm; 2005 Mar; 291(1-2):127-37. PubMed ID: 15707739
[TBL] [Abstract][Full Text] [Related]
9. Rapid and simple stability indicating HPLC method for the determination of cilazapril in pure substance and pharmaceutical formulation in comparison with classic and derivative spectrophotometric methods.
Paszun SK; Stanisz B; Pawłowski W
Acta Pol Pharm; 2012; 69(2):193-201. PubMed ID: 22568033
[TBL] [Abstract][Full Text] [Related]
10. Stability of captopril in SyrSpend SF.
Geiger CM; Sorenson B; Whaley PA
Int J Pharm Compd; 2013; 17(4):336-8. PubMed ID: 24261148
[TBL] [Abstract][Full Text] [Related]
11. Stability of cilazapril in pediatric oral suspensions prepared from commercially available tablet dosage forms.
Stanisz BJ; Paszun SK; Zalewska A
Acta Pol Pharm; 2014; 71(4):661-6. PubMed ID: 25272892
[TBL] [Abstract][Full Text] [Related]
12. Determination of active ingredients in the pharmaceutical formulations containing hydrochlorothiazide and its binary mixtures with benazepril hydrochloride, triamterene and cilazapril by ratio spectra derivative spectrophotometry and vierordt's method.
Erk N
J Pharm Biomed Anal; 1999 Jun; 20(1-2):155-67. PubMed ID: 10704019
[TBL] [Abstract][Full Text] [Related]
13. From 'fixed dose combinations' to 'a dynamic dose combiner': 3D printed bi-layer antihypertensive tablets.
Sadia M; Isreb A; Abbadi I; Isreb M; Aziz D; Selo A; Timmins P; Alhnan MA
Eur J Pharm Sci; 2018 Oct; 123():484-494. PubMed ID: 30041029
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of degradation of enalapril maleate in dosage forms.
Stanisz B
Acta Pol Pharm; 2004; 61(6):415-8. PubMed ID: 15794332
[TBL] [Abstract][Full Text] [Related]
15. Stability of freeze-dried tablets at different relative humidities.
Corveleyn S; Remon JP
Drug Dev Ind Pharm; 1999 Sep; 25(9):1005-13. PubMed ID: 10518240
[TBL] [Abstract][Full Text] [Related]
16. Square wave voltammetric determination of the angiotensin-converting enzyme inhibitors cilazapril, quinapril and ramipril in pharmaceutical formulations.
Prieto JA; Jiménez RM; Alonso RM
Farmaco; 2003 May; 58(5):343-50. PubMed ID: 12729827
[TBL] [Abstract][Full Text] [Related]
17. Design of a pediatric oral formulation with a low proportion of hydrochlorothiazide.
Santoveña A; Hernández-Paiz Z; Fariña JB
Int J Pharm; 2012 Feb; 423(2):360-4. PubMed ID: 22155411
[TBL] [Abstract][Full Text] [Related]
18. Influence of humidity and hydroxypropyl cellulose, hydroxypropylmethyl cellulose, glyceryl behenate or magnesium stearate on the degradation kinetics of quinapril hydrochloride in solid phase.
Stanisz B; Paszun S; Strzyzycka N; Ptaszyński E
Acta Pol Pharm; 2010; 67(1):99-102. PubMed ID: 20210086
[TBL] [Abstract][Full Text] [Related]
19. Influence of formulation properties on chemical stability of captopril in aqueous preparations.
Kristensen S; Lao YE; Brustugun J; Braenden JU
Pharmazie; 2008 Dec; 63(12):872-7. PubMed ID: 19177902
[TBL] [Abstract][Full Text] [Related]
20. Quality by design development of brivanib alaninate tablets: degradant and moisture control strategy.
Badawy SI; Lin J; Gokhale M; Desai S; Nesarikar VV; LaMarche KR; Subramanian GA; Narang AS
Int J Pharm; 2014 Jul; 469(1):111-20. PubMed ID: 24780101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
